Palumbo Wealth Management LLC Purchases 11,792 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Palumbo Wealth Management LLC grew its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 97.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,932 shares of the company’s stock after acquiring an additional 11,792 shares during the period. Palumbo Wealth Management LLC’s holdings in Ventyx Biosciences were worth $52,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of VTYX. The Manufacturers Life Insurance Company raised its position in Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the last quarter. SG Americas Securities LLC boosted its stake in Ventyx Biosciences by 149.8% in the 3rd quarter. SG Americas Securities LLC now owns 34,670 shares of the company’s stock worth $76,000 after purchasing an additional 20,792 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the period. LMR Partners LLP acquired a new position in Ventyx Biosciences in the 3rd quarter worth $218,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Ventyx Biosciences by 10.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 462,170 shares of the company’s stock worth $1,008,000 after purchasing an additional 42,600 shares during the period. Institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on VTYX. Oppenheimer reissued an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Ventyx Biosciences presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Trading Up 1.8 %

NASDAQ VTYX opened at $1.71 on Monday. The firm has a market capitalization of $120.91 million, a price-to-earnings ratio of -0.72 and a beta of 0.52. The firm’s 50 day simple moving average is $2.14 and its 200 day simple moving average is $2.18. Ventyx Biosciences, Inc. has a 1 year low of $1.57 and a 1 year high of $11.48.

Insider Buying and Selling

In related news, Director Sheila Gujrathi acquired 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $2.31 per share, with a total value of $300,300.00. Following the purchase, the director now directly owns 130,000 shares in the company, valued at approximately $300,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider John Nuss sold 13,161 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the completion of the transaction, the insider now directly owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 630,000 shares of company stock worth $1,262,415. Corporate insiders own 18.18% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.